Yazılar

Nabla Bio and Takeda deepen AI-powered drug discovery partnership

/in /tarafından

U.S. biotech startup Nabla Bio has expanded its collaboration with Japanese pharmaceutical giant Takeda, signing a new multi-year agreement to further integrate artificial intelligence (AI) into the drug discovery process.

The partnership, building on an initial 2022 deal, includes upfront and research payments in the double-digit millions, with Nabla eligible for success-based milestones exceeding $1 billion. The companies will use Nabla’s proprietary Joint Atomic Model (JAM) platform to design next-generation protein-based therapeutics, including multi-specific drugs targeting hard-to-treat diseases.

Nabla CEO Surge Biswas described JAM as a system that “responds to molecular queries the way ChatGPT answers text questions,” generating custom antibody designs that meet specific biological targets. The company says its technology offers one of the fastest feedback loops in the biotech sector — only three to four weeks from computational design to laboratory testing.

Takeda’s renewed focus on scalable, AI-driven drug types follows its decision to exit cell therapy research earlier this year. The Japanese firm also recently joined a consortium with Bristol Myers Squibb to develop AI models using shared pharmaceutical data.

Nabla expects to deliver first-in-human data from its AI-designed therapeutics within one to two years, marking another milestone in the industry’s growing reliance on AI to cut development timelines and boost innovation.

JSR’s Incoming CEO to Prioritize Financial Recovery, Shifts Away from M&A Plans

/in /tarafından

Tetsuro Hori, the incoming CEO of Japanese chip materials maker JSR, has signaled a strategic shift in focus toward financial recovery rather than industry consolidation. Hori, who will assume his role on April 1, emphasized that JSR’s current financial struggles make it unprepared for acquisitions.

Key Priorities and Potential Divestment

Hori highlighted the urgent need to improve JSR’s life sciences business, which has suffered losses and impacted overall performance. Industry speculation has grown regarding a possible sale of the division, a scenario Hori has not ruled out. “JSR might not be the best owner of the life science business,” he admitted, though he stressed that any decision would depend on improved financial performance.

Change in Strategy from Previous Leadership

Under outgoing CEO Eric Johnson, JSR was taken private last year in a $6 billion buyout by Japan Investment Corp (JIC). Johnson had argued that being privately held would enable JSR to pursue mergers and acquisitions more freely. However, this approach has faced skepticism within the industry, and Hori now indicates a more cautious stance.

“M&A must be supported by customers and create value,” Hori stated, implying that large-scale acquisitions are not currently on the agenda.

Industry Partnerships and Financial Outlook

While Hori acknowledged the possibility of collaborations, he noted that there have been no discussions with Resonac, another chip materials maker, despite industry speculation about potential synergies when JIC eventually exits JSR.

Financially, JSR reported a net loss of 22.2 billion yen ($148 million) for the six-month period ending September 30. Hori aims to restore profitability by the fiscal year ending March 2026.

Google Integrates SandboxAQ’s Quantitative AI Models into Cloud Services

/in /tarafından

Google Cloud has expanded its offerings by integrating SandboxAQ’s large quantitative models (LQMs), designed to process complex numerical data and perform advanced statistical analysis. This move highlights the growing interest of cloud providers in AI technology as a key driver of future growth.

Key Points:

  • Partnership with SandboxAQ: Quantum startup SandboxAQ has announced that its LQMs will be available on Google Cloud, making it easier for businesses to use and deploy these models. SandboxAQ, a spin-off of Google-parent Alphabet, is seeking to expand its reach and customer base through this collaboration.
  • Capabilities of LQMs: The models are designed to handle large-scale datasets and perform intricate calculations, ideal for creating advanced financial models, automating trading strategies, and addressing complex business problems. These models are particularly useful in industries like life sciences, financial services, and navigation.
  • Quantum AI Synergy: According to SandboxAQ CEO Jack Hidary, quantitative AI is essential for many sectors of the economy, especially where mathematical and quantitative relationships are fundamental. He emphasized the complementary nature of quantitative AI and language models in solving complex challenges.
  • SandboxAQ’s Growth: In the previous month, SandboxAQ raised $300 million in funding, which boosted its valuation to $5.6 billion. The company is backed by prominent investors including Fred Alger Management, T. Rowe Price, and Breyer Capital.
  • Broader Industry Impacts: Google’s push into quantum computing, including progress on new quantum chips, is seen as part of its broader strategy to lead in this emerging field. Competitors such as Microsoft and Nvidia have also been active in exploring quantum computing, although practical applications are still seen as years away.